Quantcast

Latest Lymphocytic Leukemia Stories

2014-02-12 08:22:51

DUBLIN, Feb. 12, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/x4z6dv/acute ) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries to 2020" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on existing regimens and drugs, pipeline...

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...

2014-01-24 11:25:34

Results on test of Idelalisib suggest CLL may be treated without toxic chemotherapy Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team. Their findings on the therapy for chronic lymphocytic leukemia (CLL), reported in the Jan. 22 issue of the New England Journal of Medicine, suggest that patients may be able to avoid having to take debilitating...

2014-01-23 16:24:44

Grant Program Addresses Three Critical Areas of Blood Cancer Research WHITE PLAINS, N.Y., Jan. 23, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the fourteen researchers who will receive funding through the Quest for Cures program - a new grant program that addresses three critical areas of blood cancer research. The three priority areas are: monitoring tumor cell heterogeneity and its contribution to response or resistance to therapy; molecular...

2014-01-21 23:21:44

Acute Lymphocytic / Lymphoblastic Leukemia Therapeutics Market report categorizes the market in G8 countries into the following segments by Drug and by Geography. http://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html (PRWEB) January 21, 2014 The “Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)” analyzes and studies the major market drivers,...

2014-01-09 23:01:40

Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia, PA (PRWEB) January 09, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1910, a randomized phase III clinical trial comparing overall survival after treatment with blinatumomab in combination with chemotherapy vs. chemotherapy alone in adults aged 35 to...

2014-01-07 12:27:02

RARITAN, N.J., Jan. 7, 2014 /PRNewswire/ -- Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA(TM) (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant difference in progression-free survival (PFS) as compared to the control, the...

2014-01-07 12:26:56

SUNNYVALE, Calif., Jan. 7, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that an Independent Data Monitoring Committee (IDMC) unanimously recommended that the Phase III RESONATE study, PCYC-1112-CA, a head-to-head comparison of IMBRUVICA(TM) (ibrutinib) versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met. At the planned interim analysis, the Phase III RESONATE study demonstrated that IMBRUVICA showed...

2013-12-16 23:21:01

RnRMarketResearch.com adds “Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 – 2020)” to its store. The growing acute lymphocytic leukemia population is an impetus for the growth of the market. Dallas, TX (PRWEB) December 16, 2013 The acute lymphocytic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic leukemia is...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related